Menopause: the phase we've spent a century treating as a disease, and what the evidence actually says

A history of getting it wrong

If perimenopause inherited a reputation for hysteria, menopause inherited something almost worse: the idea that a woman past her reproductive years had, in some sense, stopped being useful—medically, socially, even biologically. For most of history, the end of menstruation was treated less as a transition and more as a verdict.

Even as medicine began taking menopause more seriously, the conversation often swung between two extremes. For decades, it was dismissed as "just getting old" and something to be quietly endured. Later, the pendulum swung the other way, and menopause came to be framed as a hormone deficiency disease, with blanket treatment recommended regardless of the individual woman in front of the doctor. Both extremes got something fundamentally wrong. Menopause is neither a decline to be ignored nor a deficiency to be universally medicated. It is a normal and defined biological event and what a woman needs from it depends entirely on her.

Unlike perimenopause, menopause itself is easy to define: it is a single point in time, twelve consecutive months after a woman's final menstrual period, recognised only in hindsight.

What it actually feels like

By the time a woman reaches menopause, many of the symptoms she experienced during perimenopause are already familiar. What changes is the texture underneath them. Where perimenopause was defined by fluctuation, menopause is defined by a new, low, stable baseline.

Hot flushes and night sweats often persist into menopause, sometimes for a decade or more. The mechanism is the same hypersensitive hypothalamic thermostat seen in perimenopause, but now operating against a backdrop of consistently low oestrogen rather than erratic swings.

It's worth pausing here on something that gets lost in most menopause conversations. Many of the complaints commonly blamed on menopause, such as fatigue, irritability, headaches, insomnia, low mood, palpitations are genuinely common in midlife, but their link to oestrogen is often weaker than the popular narrative suggests. The study of menopause has long been shaped by social and cultural belief as much as by science, and problems arising from life events like caregiving responsibilities, loss, work pressures, shifting relationships have often been too quickly filed under "menopause." Reliable community-based data now tell us that much of the increase in symptoms women report at midlife reflects these personal and social circumstances, not the hormonal events of menopause itself. Hormones are an easy explanation. They are rarely the whole one.

Genitourinary syndrome of menopause (GSM) becomes more prominent over time, not less. This is an important distinction worth making clear to women: GSM is a chronic condition that does not resolve without treatment, and symptoms can return if treatment is stopped unlike vasomotor symptoms, which tend to ease with time on their own.

There is also a significant, often invisible shift in body composition during this transition. Weight gain and changes in body composition are extremely common at this stage of life though it's worth noting that most of this midlife weight gain is actually driven by the general process of aging rather than by menopause itself. What menopause specifically drives is the redistribution of that weight—the decline in oestrogen is the major reason fat shifts toward the abdomen during this period. And this matters clinically: increased abdominal fat carries significant cardiometabolic risk even in women whose overall BMI looks completely normal. This is one of the most under-recognised risk markers in midlife women—a woman can look "fine" on the scale and still be carrying meaningfully elevated cardiovascular risk.

Bone health enters the picture in earnest here. The years immediately following menopause see the steepest rate of bone loss a woman will experience in her lifetime. This is silent and there is no symptom that announces declining bone density until a fracture does it instead.

Cardiovascular risk shifts too. Before menopause, oestrogen offers a degree of cardiovascular protection. After menopause, that protection is gone, and a woman's cardiovascular risk profile begins to converge with that of her male peers of the same age.

Cognitive symptoms that began in perimenopause—the fog, the word-finding difficulty often improve once hormone levels stabilize, even at a lower baseline. This is one of the few genuinely reassuring patterns in this transition.

The diagnosis is simple. The implications are not.

Unlike perimenopause, menopause genuinely is straightforward to diagnose—clinically, in most cases, without any blood test at all. Twelve consecutive months without a period, in a woman of the expected age, with no other explanation, is menopause. That's it.

For the vast majority of women presenting at the expected age with the expected history, ordering FSH or oestradiol adds little. What matters far more at this stage is not confirming what has already happened, but assessing what it means going forward.

This also means that hot flushes alone shouldn't automatically be filed under "menopause," even in women of the expected age. Premenopausal women presenting with hot flushes deserve screening for thyroid disease and other conditions that can produce the same picture, rather than an assumption that hormones explain everything.

And there's a broader point here that's easily missed. Clinicians should stay alert to the possibility that an underlying emotional difficulty is presenting as a physical or menopausal complaint. Looking beyond the symptom, into the actual context of a woman's life, is a service that's easy to underestimate at the moment and one that patients and families come to value far more than a prescription. It is, admittedly, the harder path. Writing a script for oestrogen takes a few minutes. Sitting with the fuller picture takes longer. But it's often the only route to something that actually resolves.

Managing it: shifting from reassurance to protection

The management conversation in menopause is about protecting against the long-term consequences of a hormonal environment that is not going to change back.

Lifestyle remains foundational and the evidence here is now very clear.

Midlife women should be actively screened for weight gain, with behavioural modification, calorie restriction, and regular physical activity forming the backbone of management and these remain the most important interventions for preventing and managing midlife weight gain. Importantly, even a modest weight loss of 5 to 10% is enough to meaningfully improve many of the metabolic abnormalities associated with insulin resistance.

On exercise specifically, the evidence now gives us a clear target: at least 150 minutes of moderate-intensity exercise per week, with two additional sessions of resistance training for further benefit. This combination reduces cardiovascular and all-cause mortality and lowers the risk of falls and fractures, the outcomes that matter enormously in the postmenopausal years.

Here is where the conversation around hormone therapy needs to be especially precise.

Menopausal hormone therapy is, without question, the most effective treatment available for vasomotor symptoms—hot flushes and night sweats that markedly impair quality of life. Where available, it should be offered to women with bothersome symptoms who don't have significant contraindications and aren't averse to it. When used for this purpose, MHT is typically appropriate for women younger than 60, or within 10 years of menopause, following a full discussion of benefits and risks. Both transdermal and oral oestrogen are effective, with low to moderate doses relieving symptoms in more than 80% of postmenopausal women.

But here is the crucial distinction that often gets lost: MHT effectively manages menopausal symptoms, but it does not have a direct impact on body weight, and it should not be prescribed for weight management or to improve body composition. While oestrogen-based MHT can favourably influence fat distribution and insulin resistance to some degree, this is not and should never be the reason it is prescribed. The two conversations need to stay separate. A woman should not start MHT expecting it to be a weight-loss intervention, and should not be denied it for symptom relief because she's "not that overweight."

For genitourinary symptoms, local vaginal oestrogen provides targeted relief with negligible systemic absorption, and should be offered to improve genitourinary and sexual symptoms associated with menopause. Vaginal lubricants and moisturisers also have a clear role here, and can be used either alone or alongside other treatments. They're a simple, accessible first step that's often underused. It's also worth being upfront with women: there isn't currently good evidence on the role of systemic or vaginal testosterone specifically for treating GSM, so this isn't something to reach for in this context.

This is the piece that the 2002 Women's Health Initiative study muddied for two decades — a study conducted in older, predominantly postmenopausal women using oral conjugated equine oestrogen and synthetic progestins, whose findings were generalised far beyond the population and formulations actually studied. The transdermal, body-identical preparations used today carry a different risk profile, particularly when started in the appropriate window.

A note on "bioidentical" hormones

This is a conversation that comes up often, and it deserves a clear, evidence-based answer. Compounded bioidentical hormone therapy is not recommended—not because the idea of body-identical hormones is wrong (regulated MHT often is body-identical), but because compounded preparations lack the quality control, regulatory oversight, and safety testing that licensed MHT undergoes. The use of blood or salivary hormone testing to "personalise" compounded doses is also not supported by major menopause societies—hormone levels fluctuate too much for this to be a meaningful guide. Women asking about this should be reassured that licensed MHT already comes in a wide range of doses and delivery methods, allowing genuine individualisation—without the safety uncertainty that comes with compounded preparations.

For women who cannot or choose not to use MHT, non-hormonal options remain—SSRIs and SNRIs, fezolinetant, and local vaginal oestrogen for GSM, which carries negligible systemic absorption and sits in a different risk category from systemic therapy altogether.

Menopause as an opportunity

If perimenopause is the moment a woman starts paying attention, menopause is where that attention pays off—or where its absence starts to cost her. The years immediately following menopause are, in many ways, the highest-leverage years in preventive women's health.

This is not a phase to be endured quietly until it passes, because unlike perimenopause, it does not pass — rather, it is the new baseline. But a new baseline, addressed properly, is not a diminished one. With the right attention to bone, heart, hormones, and lifestyle, the postmenopausal decades can be among the healthiest and most stable of a woman's life. The work now is not about waiting it out. It's about building forward.